GlassScriptPhysician profile
Vijay Bhasin
NPI 1780684142
$1,389.41
in general payments reported to CMS, 2019-2025
14 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2021: $224 · 2022: $187 · 2023: $382 · 2024: $147 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.19 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $274.65 | 2019-2025 | Tavneos |
| Travere Therapeutics, INC. | $187.55 | 2023-2025 | Filspari |
| E.R. Squibb & Sons, L.L.C. | $128.03 | 2023 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $122.88 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.75 | 2022-2023 | |
| Nevro Corp. | $100.72 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $78.21 | 2019-2024 | Jynarque |
| Ardelyx, INC. | $77.82 | 2025 | Xphozah 30 Mg |
| Calliditas Therapeutics US INC. | $76.30 | 2023 | Tarpeyo |
| Bard Peripheral Vascular, INC. | $62.70 | 2019 | |
| Akebia Therapeutics INC | $61.15 | 2019 | |
| Lilly USA, LLC | $49.24 | 2024 | Jardiance |
| Lundbeck LLC | $39.89 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.